CN113508134B - 白蛋白结合抗体及其用途 - Google Patents

白蛋白结合抗体及其用途 Download PDF

Info

Publication number
CN113508134B
CN113508134B CN202080015296.8A CN202080015296A CN113508134B CN 113508134 B CN113508134 B CN 113508134B CN 202080015296 A CN202080015296 A CN 202080015296A CN 113508134 B CN113508134 B CN 113508134B
Authority
CN
China
Prior art keywords
amino acid
seq
acid sequence
albumin
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080015296.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN113508134A (zh
Inventor
钟子洋
叶帆
马修.西格
黄嘉宁
埃里克·寥
伊娜·李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avida Biotechnology Co
Original Assignee
Avida Biotechnology Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avida Biotechnology Co filed Critical Avida Biotechnology Co
Publication of CN113508134A publication Critical patent/CN113508134A/zh
Application granted granted Critical
Publication of CN113508134B publication Critical patent/CN113508134B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN202080015296.8A 2019-02-22 2020-02-21 白蛋白结合抗体及其用途 Active CN113508134B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962809475P 2019-02-22 2019-02-22
US62/809,475 2019-02-22
PCT/US2020/019215 WO2020172528A1 (en) 2019-02-22 2020-02-21 Albumin binding antibodies and use thereof

Publications (2)

Publication Number Publication Date
CN113508134A CN113508134A (zh) 2021-10-15
CN113508134B true CN113508134B (zh) 2024-12-03

Family

ID=72144485

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080015296.8A Active CN113508134B (zh) 2019-02-22 2020-02-21 白蛋白结合抗体及其用途

Country Status (6)

Country Link
US (1) US12479909B2 (enExample)
EP (1) EP3927740A4 (enExample)
JP (1) JP2022520998A (enExample)
CN (1) CN113508134B (enExample)
TW (1) TW202045545A (enExample)
WO (1) WO2020172528A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
JP2021527706A (ja) * 2018-06-18 2021-10-14 アンウィタ バイオサイエンシス， インク． 抗メソテリンコンストラクト及びその使用
WO2021102063A1 (en) 2019-11-20 2021-05-27 Anwita Biosciences, Inc. Cytokine fusion proteins, and their pharmaceutical compositions and therapeutic applications
EP4143329A4 (en) 2020-04-28 2024-10-16 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
EP4171611A4 (en) 2020-07-30 2024-10-02 Anwita Biosciences, Inc. Interleukin-22 fusion proteins, and their pharmaceutical compositions and therapeutic applications
CN116419973A (zh) * 2020-10-02 2023-07-11 新加坡科技研究局 用于蛋白质生产和筛选的表达系统
WO2022104236A2 (en) * 2020-11-16 2022-05-19 Ab Therapeutics, Inc. Multispecific antibodies and uses thereof
JP2023552462A (ja) * 2020-12-08 2023-12-15 ジャナックス セラピューティクス，インク． 半減期延長組成物および方法
CN117545504A (zh) * 2021-06-07 2024-02-09 上海济煜医药科技有限公司 抗人血清白蛋白的抗原结合蛋白
WO2023215810A1 (en) * 2022-05-05 2023-11-09 Inhibrx, Inc. Albumin-binding polypeptides and uses thereof
JP2025526875A (ja) * 2022-08-17 2025-08-15 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 改善された抗アルブミンナノボディおよびその使用
WO2024051796A1 (en) * 2022-09-09 2024-03-14 Wuxi Biologics (Shanghai) Co., Ltd. Albumin binding proteins, fusion proteins and uses thereof
WO2024097639A1 (en) * 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
WO2024170756A1 (en) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides binding to the neonatal fc receptor
WO2024236068A1 (en) * 2023-05-17 2024-11-21 Navigo Proteins Affinity ligand for a single chain antibody fragment specific for serum albumin
NL2036011B1 (en) 2023-10-12 2025-04-30 Synapse Res Institute Molecules for reversing anti-coagulant activity of direct oral anticoagulants

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016187594A1 (en) * 2015-05-21 2016-11-24 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
WO2017080850A1 (en) * 2015-11-13 2017-05-18 Ablynx Nv Improved serum albumin-binding immunoglobulin variable domains

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1558646A2 (en) * 2002-11-08 2005-08-03 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses thereof
US9156914B2 (en) * 2006-12-19 2015-10-13 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
EP2692736B1 (en) * 2008-10-14 2018-04-18 National Research Council Of Canada Bsa-specific antibodies
EA201270174A1 (ru) * 2009-07-16 2012-07-30 Глэксо Груп Лимитед Отдельные связывающиеся вариабельные домены с улучшенными свойствами, направленные против сывороточного альбумина
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
SG188204A1 (en) * 2010-08-20 2013-04-30 Glaxo Group Ltd Improved anti-serum albumin binding variants
US9670275B2 (en) * 2012-01-23 2017-06-06 Ablynx N.V. Sequences directed against hepatocyte growth factor (HGF) and polypeptides comprising the same for the treatment of cancers and/or tumors
DK3564260T5 (da) 2012-02-15 2024-09-02 Bioverativ Therapeutics Inc Faktor viii-sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
WO2016034968A1 (en) * 2014-09-02 2016-03-10 Pfizer Inc. Therapeutic antibody
WO2016081639A1 (en) * 2014-11-19 2016-05-26 Genentech, Inc. Antibodies against bace1 and use thereof for neural disease immunotherapy
IL263102B2 (en) 2016-05-20 2023-11-01 Harpoon Therapeutics Inc A serum albumin-binding protein with a single site
RU2022101604A (ru) * 2016-12-07 2022-03-29 Аблинкс Нв Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином
KR102376863B1 (ko) 2017-05-12 2022-03-21 하푼 테라퓨틱스, 인크. 메소텔린 결합 단백질
UY37829A (es) * 2017-08-03 2019-01-31 Amgen Inc Muteínas de interleucina 21 y métodos de tratamiento
CA3076250A1 (en) * 2017-10-02 2019-04-11 Vib Vzw Compounds to inhibit bacterial s-layer protein assembly
JP2021527706A (ja) 2018-06-18 2021-10-14 アンウィタ バイオサイエンシス， インク． 抗メソテリンコンストラクト及びその使用
WO2021102063A1 (en) * 2019-11-20 2021-05-27 Anwita Biosciences, Inc. Cytokine fusion proteins, and their pharmaceutical compositions and therapeutic applications
EP4171611A4 (en) * 2020-07-30 2024-10-02 Anwita Biosciences, Inc. Interleukin-22 fusion proteins, and their pharmaceutical compositions and therapeutic applications

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016187594A1 (en) * 2015-05-21 2016-11-24 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
WO2017080850A1 (en) * 2015-11-13 2017-05-18 Ablynx Nv Improved serum albumin-binding immunoglobulin variable domains

Also Published As

Publication number Publication date
TW202045545A (zh) 2020-12-16
US20220195021A1 (en) 2022-06-23
WO2020172528A8 (en) 2021-10-07
JP2022520998A (ja) 2022-04-04
CN113508134A (zh) 2021-10-15
EP3927740A1 (en) 2021-12-29
WO2020172528A1 (en) 2020-08-27
US12479909B2 (en) 2025-11-25
EP3927740A4 (en) 2023-03-01

Similar Documents

Publication Publication Date Title
CN113508134B (zh) 白蛋白结合抗体及其用途
JP7544937B2 (ja) Ｔｉｇｉｔに対する単一ドメイン抗体及びその変異体
TWI802633B (zh) 針對pd-1之單域抗體及其變異體
WO2019096121A1 (en) Single-domain antibodies and variants thereof against pd-l1
JP7346790B2 (ja) Ｌａｇ‐３に対する単一ドメイン抗体およびその使用
WO2018068201A1 (en) Single-domain antibodies and variants thereof against ctla-4
TW201930349A (zh) 多重特異性抗原結合蛋白及其使用方法
CN116888153A (zh) 与γ-δT细胞受体结合的抗体
TWI870360B (zh) 雙特異性抗體構建體之下游加工
JP2024511424A (ja) 抗ｉｇｆｂｐ７構築物およびその使用
CN119486756A (zh) 包含结合γ-δ T细胞受体的抗体的组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant